Skip to main content
In stock|Targeted Therapy (Investigational Antibody / ADC)

Raludotatug Deruxtecan

Oncology TypeSolid Tumour
Drug Class / MechanismAnti-CDH6 ADC, Topoisomerase I Inhibitor Payload
No Image
Description

Raludotatug Deruxtecan is classified as an Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload, sourced for use within our Targeted Therapy (Investigational Antibody / ADC) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Investigational Antibody / ADC)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3